Skip to main content
. Author manuscript; available in PMC: 2014 Oct 24.
Published in final edited form as: Cell. 2013 Oct 24;155(3):10.1016/j.cell.2013.09.061. doi: 10.1016/j.cell.2013.09.061

Figure 3. Protective Efficacy Against SHIV-SF162P3 Challenges.

Figure 3

(A) Number of challenges required for acquisition of infection in each vaccine group.

(B) Statistical analyses include hazard ratios with 95% confidence intervals (CI), the per-exposure reduction in acquisition risk, and the absolute percentage of uninfected animals in each group after 1, 3, and 6 challenges. P-values reflect Cox proportional hazard model.

(C) Log peak SIV RNA copies/ml are depicted for each group. P-values represent Wilcoxon rank-sum tests. Box-and-whisker plots are shown.

(D) Log setpoint SIV RNA copies/ml are depicted for each group at day 70. Box-and-whisker plots are shown.

(E) Clinical survival curve.

(F) Statistical analyses of survival at 250 days following challenge. P-values reflect Fisher's exact tests comparing the vaccinated groups to the control group.